SCHEMBL8937353

SCHEMBL8937353

CCc1ccc(C(=CC(=O)N2CCN(C(=O)c3cc(OC)c(OC)c(OC)c3)CC2)c2cccc(Cl)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
CYP1A2 P05177 1/20 0.53
LMNA P02545 4/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.48
GAA P10253 2/20 0.48
HTT P42858 2/20 0.48
KDM4E B2RXH2 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
POLB P06746 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937350 1.00 ALDH1A1 (0.53) ALDH1A1CYP1A2LMNAL3MBTL1SMN1; SMN2
SCHEMBL8937557 0.92 ALDH1A1 (0.52) ALDH1A1CYP1A2LMNAL3MBTL1SMN1; SMN2
SCHEMBL8937562 0.92 ALDH1A1 (0.52) ALDH1A1CYP1A2LMNAL3MBTL1SMN1; SMN2
SCHEMBL8937475 0.91 ALDH1A1 (0.62) ALDH1A1CYP1A2LMNAL3MBTL1SMN1; SMN2
SCHEMBL8937460 0.90 ALDH1A1 (0.64) ALDH1A1CYP1A2LMNAL3MBTL1CYP3A4
SCHEMBL8937471 0.90 ALDH1A1 (0.64) ALDH1A1CYP1A2LMNAL3MBTL1CYP3A4
SCHEMBL8937467 0.90 ALDH1A1 (0.64) ALDH1A1CYP1A2LMNAL3MBTL1CYP3A4
SCHEMBL8937243 0.89 ALDH1A1 (0.58) ALDH1A1CYP1A2LMNAL3MBTL1SMN1; SMN2
SCHEMBL8937247 0.89 ALDH1A1 (0.58) ALDH1A1CYP1A2LMNAL3MBTL1SMN1; SMN2
SCHEMBL8937245 0.89 ALDH1A1 (0.58) ALDH1A1CYP1A2LMNAL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US claimed
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed